On September 17, Novo-Nordisk A/S rose 3.07% in regular trading, trading at $42.98 per share, with turnover of $135 million. The gain was driven by the announcement of a major strategic collaboration with Danish biotech firm Orbis Medicines.

Orbis Medicines announced it has entered into a strategic collaboration and license agreement with Novo-Nordisk A/S to co-develop oral macrocycle therapeutics targeting cardiometabolic diseases. Under the deal, Orbis could receive up to $1.4 billion in upfront payments, development and commercial milestone payments, along with tiered royalties on future product sales. Novo-Nordisk A/S will also make a strategic investment in Orbis. The partnership leverages Orbis's AI-enabled macrocycle discovery platform combined with Novo's deep expertise in obesity and cardiometabolic disease.

The deal follows a series of AI-focused moves by Novo-Nordisk A/S, including a collaboration with Anthropic announced just a day earlier to deploy frontier AI models in drug discovery workflows. The company is also preparing for a Capital Markets Day on September 21, where it will unveil details of its updated corporate strategy under the rebranded name \"Novo.\"

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)